Pharmaceutical Executive September 29, 2025
Mike Hollan

Key Takeaways

  • Professor Riedemann’s company was founded to translate complement system research into clinical applications, aiming to improve patient care.
  • The pandemic shifted healthcare priorities, but focus is returning to pre-pandemic priorities, including dermatological conditions treatable by complement system targeting.
  • Gohibic received Emergency Use Authorization for severe COVID-19 cases, highlighting the need for preparedness in future pandemics.
  • Stocking drugs for severe infections and inflammation in ICUs may support future pandemic preparedness.

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a post-pandemic world.

Pharmaceutical Executive: What inspired you to found your own company?
Professor Niels Riedemann, MD: To be honest, I never thought I would start my own company. First and...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Trends
Related Articles:
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat

Share Article